GRB2 and melanoma: In melanoma cells, ERK rebound upon BRAFV600E inhibition may be due to reduction of the ERK phosphatase DUSP6 and receptor tyrosine kinase blocker Spry2, which sequesters the Grb2:SOS complex, preventing the binding of receptor tyrosine kinase [23].